Lahore: Highnoon Laboratories Limited has confirmed its commitment to its shareholders by approving a 400% cash dividend during its 42nd Annual General Meeting, held on April 29, 2025. The meeting, which focused on ordinary business matters, addressed the company's financial and operational outcomes for the fiscal year ending December 31, 2024.

Shareholders of Highnoon Laboratories Limited confirmed the minutes from the previous Extraordinary General Meeting, which took place on September 2, 2024. This confirmation marks a procedural step in maintaining the company's governance protocols and ensuring transparency in its operations.

The meeting also involved the adoption of the Chairman's Review Report along with the Directors' and Auditors' Reports. The financial statements for the fiscal year ending December 31, 2024, both separate and consolidated, were presented and approved by the members. This approval reflects the company's financial health and operational performance over the past year.

One of the key resolutions passed was the approval of a final cash dividend of Rs. 40 per share, representing a 400% payout for the year ended December 31, 2024. This move aligns with the recommendations of the Board of Directors, confirmed during their meeting on March 26, 2025.

Additionally, BDO Ebrahim & Co, Chartered Accountants, were reappointed as the company's auditors for the upcoming fiscal year. The decision regarding their remuneration will be mutually agreed upon, ensuring that the company's auditing processes continue to meet professional standards.

According to information available from the Pakistan Stock Exchange (PSX), Highnoon Laboratories Limited operates within the designated market category, maintaining its role in the pharmaceutical sector. The company's financial strategies and resolutions from the recent meeting underscore its focus on delivering value to shareholders while adhering to corporate governance standards.